Precancerous Condition Clinical Trial
Official title:
Phase I Trial Of Pirfenidone In Children With Neurofibromatosis Type 1 And Plexiform Neurofibromas
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development or recurrence of cancer. Pirfenidone may slow the growth or prevent further
development of plexiform neurofibromas.
PURPOSE: Phase I trial to study the effectiveness of pirfenidone in treating young patients
who have neurofibromatosis type 1 and plexiform neurofibroma.
OBJECTIVES:
- Determine the maximum tolerated dose or "comparable dose" of pirfenidone in pediatric
patients with neurofibromatosis type 1 and inoperable, symptomatic plexiform
neurofibromas.
- Determine the toxic effects of this drug in these patients.
- Determine the plasma pharmacokinetics of this drug in these patients.
- Determine, preliminarily, if this drug could be beneficial for pediatric patients with
refractory solid tumors.
- Assess the quality of life of patients treated with this drug.
OUTLINE: This is an open-label, multicenter, dose-escalation study.
Patients receive oral pirfenidone three times daily on days 1-28. Courses repeat every 28
days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of pirfenidone until the maximum tolerated
dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2
of 6 patients experience dose-limiting toxicity.
Quality of life is assessed at baseline, before course 4, and then after every 6 courses.
PROJECTED ACCRUAL: A total of 3-18 patients will be accrued for this study within 18 months.
;
Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
| Completed |
NCT00653146 -
The Effects of MBSR in Improving Immune Response to Human Papillomavirus in Patients With Cervical Dysplasia
|
N/A | |
| Completed |
NCT00550589 -
Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
|
Phase 2 | |
| Terminated |
NCT00629577 -
Gene Expression Profiling of Cervical Cancer Progression in Biopsies and Tissue Samples
|
Phase 1 | |
| Completed |
NCT00103246 -
Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides
|
Phase 1 | |
| Completed |
NCT00066430 -
Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
|
Phase 1 | |
| Completed |
NCT00522197 -
ACAPHA in Preventing Lung Cancer in Former Smokers With Bronchial Intraepithelial Neoplasia
|
Phase 2 | |
| Completed |
NCT00003384 -
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer
|
N/A | |
| Terminated |
NCT02574442 -
Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer
|
||
| Completed |
NCT00719563 -
American Ginseng in Treating Patients With Fatigue Caused by Cancer
|
Phase 3 | |
| Terminated |
NCT00899951 -
Studying Fentanyl in Patients With Cancer
|
N/A | |
| Terminated |
NCT00611650 -
Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia
|
Phase 2 | |
| Completed |
NCT00873288 -
Activating Collaborative CIS Support Via Targeted Provider Mailing
|
N/A | |
| Completed |
NCT00462813 -
Diindolylmethane in Treating Patients With Abnormal Cervical Cells
|
Phase 3 | |
| Completed |
NCT00006348 -
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
|
Phase 3 | |
| Completed |
NCT00666731 -
Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer
|
||
| Recruiting |
NCT04445532 -
Hepatobiliary Tumors Tissue Samples Acquisition
|
||
| Completed |
NCT00685568 -
Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis
|
Phase 1 | |
| Terminated |
NCT00942422 -
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT00788164 -
Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia
|
Phase 1 |